keyword
MENU ▼
Read by QxMD icon Read
search

Disease-modifying antirheumatic drugs

keyword
https://www.readbyqxmd.com/read/29134891/efficacy-and-safety-of-baricitinib-in-japanese-patients-with-rheumatoid-arthritis-subgroup-analyses-of-four-multinational-phase-3-randomized-trials
#1
Yoshiya Tanaka, Tatsuya Atsumi, Koichi Amano, Masayoshi Harigai, Taeko Ishii, Osamu Kawaguchi, Terence P Rooney, Naotsugu Akashi, Tsutomu Takeuchi
OBJECTIVES: To evaluate efficacy/safety of baricitinib for rheumatoid arthritis (RA) in Japanese subpopulations from four phase 3 studies, and assess whether results in these subpopulations are consistent with the overall study populations. METHODS: Subgroup analyses (394 patients) of four phase 3 randomized controlled trials: RA-BEGIN [no or limited treatment with disease-modifying antirheumatic drugs (DMARDs)], RA-BEAM [inadequate response (IR) to methotrexate], RA-BUILD [IR to conventional synthetic DMARDs (csDMARDs)], and RA-BEACON (IR to tumor necrosis factor inhibitors receiving csDMARDs)...
November 14, 2017: Modern Rheumatology
https://www.readbyqxmd.com/read/29127626/impact-of-infliximab-and-etanercept-biosimilars-on-biological-disease-modifying-antirheumatic-drugs-utilisation-and-nhs-budget-in-the-uk
#2
Mohammed I Aladul, Raymond W Fitzpatrick, Stephen R Chapman
OBJECTIVE: Biological disease-modifying antirheumatic drugs (bDMARDs) are effective but expensive options for treating rheumatoid arthritis. The introduction of infliximab and etanercept biosimilars presents a significant potential cost saving in a financially constrained health system such as the National Health Service (NHS) in the UK. This study examines the impact of the introduction of infliximab and etanercept biosimilars on the utilisation of bDMARDs and subsequent budget impact...
November 10, 2017: BioDrugs: Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
https://www.readbyqxmd.com/read/29119581/risk-of-tuberculosis-comparison-in-new-users-of-antitumour-necrosis-factor-%C3%AE-and-with-existing-disease-modifying-antirheumatic-drug-therapy
#3
M-J Chan, Y-H Wen, Y-B Huang, H-Y Chuang, Y-L Tain, Y-C Lily Wang, C-N Hsu
WHAT IS KNOWN AND OBJECTIVE: Patients with rheumatic disease are at risk for infections. Evaluating antitumour necrosis factor (anti-TNF) drug-associated risk of infections requires justification of baseline risk in the population at high risk of infection. We examined the incidence of active tuberculosis (TB) and its risk factors in patients with rheumatic disease started with anti-TNF-α therapy or with existing disease-modifying antirheumatic drug (DMARD) therapy. METHODS: A retrospective cohort study of anti-TNF-α therapy new users (anti-TNF-α group) and those starting with a DMARD after the failure of at least one other DMARD or who had added to existing DMARD treatment (DMARD group) for rheumatic disease in the largest medical setting in Taiwan from 1 January 2005 through 31 November 2013 was conducted to determine relative risk of TB between patient groups...
November 8, 2017: Journal of Clinical Pharmacy and Therapeutics
https://www.readbyqxmd.com/read/29116003/protocols-on-classification-monitoring-and-therapy-in-children-s-rheumatology-pro-kind-results-of-the-working-group-polyarticular-juvenile-idiopathic-arthritis
#4
REVIEW
Gerd Horneff, Ariane Klein, Gerd Ganser, Michaela Sailer-Höck, Annette Günther, Ivan Foeldvari, Frank Weller-Heinemann
OBJECTIVE: Several effective pharmacologic treatment options for polyarticual juvenile idiopathic arthritis (JIA) have emerged but initial treatment is heterogeneous in Germany. Therefore, the German Society of Pediatric Rheumatolgy has established a commission to develop consensus "Protocols on classification, monitoring and therapy in children's rheumatology (PRO-KIND)" to harmonize diagnostic and treatment approaches for new-onset JIA in Germany. METHODS: A set of definitions for in- and exclusion, diagnostic workup, parameters for the evaluation of disease activity criteria, therapeutic options, medication dosing, monitoring recommendations, targets, definitions of a therapy failure and four therapeutic algorithms developed by a working group were agreed by web based survey to which all members of the GKJR have been invited...
November 7, 2017: Pediatric Rheumatology Online Journal
https://www.readbyqxmd.com/read/29111261/recommendations-of-the-spanish-society-of-rheumatology-on-treatment-and-use-of-systemic-biological-and-non-biological-therapies-in-psoriatic-arthritis
#5
Juan Carlos Torre Alonso, Petra Díaz Del Campo Fontecha, Raquel Almodóvar, Juan D Cañete, Carlos Montilla Morales, Mireia Moreno, Chamaida Plasencia-Rodríguez, Julio Ramírez García, Rubén Queiro
OBJECTIVE: The main purpose of this recommendation statement is to provide clinicians with the best available evidence and the best opinion agreed upon by the panelists for a rational use of synthetic disease modifying antirheumatic drugs (DMARDs) and biologicals in psoriatic arthritis (PsA) patients. The present document also focuses on important aspects in the management of PsA, such as early diagnosis, therapeutic objectives, comorbidities and optimization of treatment. METHODS: The recommendations were agreed by consensus by a panel of 8 expert rheumatologists, previously selected by the Spanish Society of Rheumatology (SER) through an open call...
October 27, 2017: Reumatología Clinica
https://www.readbyqxmd.com/read/29097373/predictors-of-revision-prosthetic-joint-infection-and-mortality-following-total-hip-or-total-knee-arthroplasty-in-patients-with-rheumatoid-arthritis-a-nationwide-cohort-study-using-danish-healthcare-registers
#6
Rene Lindholm Cordtz, Kristian Zobbe, Pil Højgaard, Lars Erik Kristensen, Søren Overgaard, Anders Odgaard, Hanne Lindegaard, Lene Dreyer
OBJECTIVES: To investigate predictors of 10-year risk of revision and 1-year risk of prosthetic joint infection (PJI) and death following total hip/total knee arthroplasty (THA/TKA) in (1) patients with rheumatoid arthritis (RA) compared with patients with osteoarthritis (OA); and (2) patients with RA treated with biological disease-modifying antirheumatic drugs (bDMARD) within 90 days preceding surgery compared with non-treated. METHODS: Register-based cohort study using the Danish National Patient Register, the DANBIO rheumatology register (RA-specific confounders and treatment episodes) and the Danish Hip and Knee Arthroplasty Registers...
November 2, 2017: Annals of the Rheumatic Diseases
https://www.readbyqxmd.com/read/29090371/cutaneous-manifestations-of-dermatomyositis-a-comprehensive-review
#7
REVIEW
Carlo Mainetti, Benedetta Terziroli Beretta-Piccoli, Carlo Selmi
Dermatomyositis (DM) is an idiopathic inflammatory myopathy characterized by the presence of skin lesions and inflammation of skeletal muscles; however, this feature may be absent in amyopathic DM. DM is a rare disease, occurring at any age, and has two peaks of incidence: one in childhood between 5 and 15 years of age and one in adulthood between 40 and 60 years, with a female preponderance. DM has been associated with malignancy; therefore, every newly diagnosed patient should undergo screening investigations, but evidence-based guidelines on their extension are lacking...
October 31, 2017: Clinical Reviews in Allergy & Immunology
https://www.readbyqxmd.com/read/29073669/prevalence-of-temporomandibular-disorders-in-rheumatoid-arthritis-and-associated-risk-factors-a-nationwide-study-in-taiwan
#8
Ching-Yueh Lin, Chi-Hsiang Chung, Heng-Yi Chu, Liang-Cheng Chen, Kuo-Hsien Tu, Chang-Huei Tsao, Yung-Tsan Wu, Wu-Chien Chien
AIMS: To investigate the association between temporomandibular disorders (TMD) and rheumatoid arthritis (RA), as well as potential risk factors for TMD and the preventive effect of medications on TMD, by using the Taiwan National Health Insurance Research Database. METHODS: In total, 17,317 patients newly diagnosed with RA and 17,317 matched controls without RA were followed up from 2000 to 2010. Cox regression was used to determine risk factors for developing TMD...
October 2017: Journal of Oral & Facial Pain and Headache
https://www.readbyqxmd.com/read/29071119/switching-biological-disease-modifying-antirheumatic-drugs-in-patients-with-axial-spondyloarthritis-results-from-a-systematic-literature-review
#9
Victoria Navarro-Compán, Chamaida Plasencia-Rodríguez, Eugenio de Miguel, Petra Diaz Del Campo, Alejandro Balsa, Jordi Gratacós
OBJECTIVES: First, to investigate if switching biological disease-modifying antirheumatic drugs (bDMARDs) after the failure to prior bDMARD is efficacious in patients with axial spondyloarthritis (axSpA). Second, to evaluate the influence on this efficacy of (1) the reason to discontinue prior tumour necrosis factor inhibitor (TNFi), (2) changing the type of TNFi and (3) changing the target. METHODS: A systematic literature review until January 2017 was performed using Medline, EMBASE and Cochrane databases...
2017: RMD Open
https://www.readbyqxmd.com/read/29061242/neurologic-manifestations-of-rheumatoid-arthritis
#10
REVIEW
Kimberly DeQuattro, John B Imboden
Neurologic manifestations of rheumatoid arthritis (RA) range in severity from mild paresthesias in the hand from carpal tunnel syndrome to sudden death due to impingement of the medulla by an eroded, vertically subluxed dens. Most neurologic complications are a consequence of articular inflammation and damage that leads to compression of adjacent structures of the central or peripheral nervous systems. Rare but serious extra-articular manifestations include inflammation of the meninges and ischemic neuropathies due to necrotizing arteritis of the vasa vasorum...
November 2017: Rheumatic Diseases Clinics of North America
https://www.readbyqxmd.com/read/29056774/glucocorticoid-management-in-rheumatoid-arthritis-morning-or-night-low-dose
#11
REVIEW
Sabrina Paolino, Maurizio Cutolo, Carmen Pizzorni
Morning symptoms of rheumatoid arthritis (RA) are linked to circadian increase of night inflammation, supported by inadequate cortisol secretion in active disease. Therefore, exogenous glucocorticoid administration in RA is recommended by EULAR and ACR from the beginning of the diagnosis, since may partially act like a "replacement therapy". In addition, the prevention/treatment of the night up-regulation of the immune/inflammatory reaction has been shown more effective when exogenous glucocorticoid administration is managed with a night-time-release formulation...
2017: Reumatologia
https://www.readbyqxmd.com/read/29045212/tofacitinib-or-adalimumab-versus-placebo-for-psoriatic-arthritis
#12
RANDOMIZED CONTROLLED TRIAL
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon, Thijs Hendrikx, Keith S Kanik
BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor that is under investigation for the treatment of psoriatic arthritis. We evaluated tofacitinib in patients with active psoriatic arthritis who previously had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (DMARDs). METHODS: In this 12-month, double-blind, active-controlled and placebo-controlled, phase 3 trial, we randomly assigned patients in a 2:2:2:1:1 ratio to receive one of the following regimens: tofacitinib at a 5-mg dose taken orally twice daily (107 patients), tofacitinib at a 10-mg dose taken orally twice daily (104), adalimumab at a 40-mg dose administered subcutaneously once every 2 weeks (106), placebo with a blinded switch to the 5-mg tofacitinib dose at 3 months (52), or placebo with a blinded switch to the 10-mg tofacitinib dose at 3 months (53)...
October 19, 2017: New England Journal of Medicine
https://www.readbyqxmd.com/read/29043892/tofacitinib-in-the-treatment-of-active-rheumatoid-arthritis-in-adults
#13
Roy Fleischmann
Tofacitinib, a pan Janus kinase inhibitor, has been investigated as monotherapy in patients naive to methotrexate and in methotrexate incomplete responders and in combination with disease-modifying antirheumatic drugs in antirheumatic drug incomplete responders and TNF inhibitor failures in the Phase II and III programs. The clinical trial program demonstrated efficacy and a reasonable safety profile in these disease populations that has led to the approval of tofacitinib 5 mg twice daily orally in many countries...
October 18, 2017: Immunotherapy
https://www.readbyqxmd.com/read/29043434/-spondyloarthritides
#14
M Rudwaleit
Spondyloarthritides (SpA) are inflammatory rheumatic diseases affecting the axial skeleton, peripheral joints and entheses, and also manifest at extraskeletal sites. According to the more recently introduced nomenclature, predominant axial SpA is distinguished from predominant peripheral SpA. Axial SpA is further divided into radiographic and nonradiographic axial SpA. Genetic factors are relevant, with HLA-B27 being most important. The interleukin 23/17 pathway seems to be relevant and points towards new therapeutic targets...
October 17, 2017: Zeitschrift Für Rheumatologie
https://www.readbyqxmd.com/read/29035933/psoriatic-arthritis-new-evidence-for-old-concepts
#15
Enrique R Soriano, Josefina Marin, Maria L Acosta-Felquer
PURPOSE OF REVIEW: The review gives an updated overview of some of the new concepts in the management of psoriatic arthritis (PsA): early diagnosis, remission as an objective, treat-to-target, and treatment guidelines. RECENT FINDINGS: Early diagnosis, targeting remission as part of a treatment strategy, and new guidelines providing evidence-based support to these concepts are main topics in recent publications. SUMMARY: Dermatologists and rheumatologists should work together to reduce the number of patients remaining undiagnosed, and the time to do so...
October 13, 2017: Current Opinion in Rheumatology
https://www.readbyqxmd.com/read/29033678/quantitative-metabolic-volumetric-product-on-18-fluorine-2fluoro-2-deoxy-d-glucose-positron-emission-tomography-computed-tomography-in-assessing-treatment-response-to-disease-modifying-antirheumatic-drugs-in-rheumatoid-arthritis-multiparametric-analysis-integrating
#16
Nandigam Santosh Kumar, Yogesh Shejul, Ramesh Asopa, Sandip Basu
The purpose of this study was to assess the role of fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography (FDG-PET/CT) in the evaluation of treatment response evaluation to disease-modifying antirheumatic drug (DMARD) therapy in patients of rheumatoid arthritis (RA). A total of ten patients with proven diagnosis of RA as per the 2010 American College of Rheumatology/European League against Rheumatism (EULAR) criteria were prospectively evaluated. All patients underwent clinical and biochemical evaluation and a baseline FDG-PET/CT with assessment of maximum standardized uptake value and metabolic volumetric product (MVP) values...
October 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28976302/certolizumab-pegol-and-secukinumab-for-treating-active-psoriatic-arthritis-following-inadequate-response-to-disease-modifying-antirheumatic-drugs-a-systematic-review-and-economic-evaluation
#17
Mark Corbett, Fadi Chehadah, Mousumi Biswas, Thirimon Moe-Byrne, Stephen Palmer, Marta Soares, Matthew Walton, Melissa Harden, Pauline Ho, Nerys Woolacott, Laura Bojke
BACKGROUND: Several biologic therapies are approved by the National Institute for Health and Care Excellence (NICE) for psoriatic arthritis (PsA) patients who have had an inadequate response to two or more synthetic disease-modifying antirheumatic drugs (DMARDs). NICE does not specifically recommend switching from one biologic to another, and only ustekinumab (UST; STELARA(®), Janssen Pharmaceuticals, Inc., Horsham, PA, USA) is recommended after anti-tumour necrosis factor failure. Secukinumab (SEC; COSENTYX(®), Novartis International AG, Basel, Switzerland) and certolizumab pegol (CZP; CIMZIA(®), UCB Pharma, Brussels, Belgium) have not previously been appraised by NICE...
October 2017: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/28975211/malignant-neoplasms-in-patients-with-rheumatoid-arthritis-treated-with-tumor-necrosis-factor-inhibitors-tocilizumab-abatacept-or-rituximab-in-clinical-practice-a-nationwide-cohort-study-from-sweden
#18
Hjalmar Wadström, Thomas Frisell, Johan Askling
Importance: Considering the widespread and increasing use of biological immunomodulators (biological disease-modifying antirheumatic drugs [bDMARDs]) to treat chronic inflammatory conditions, and the concern that immunomodulation may alter cancer risk and progression, the limited available data on use of these therapies as used in clinical practice and cancer risks are a concern. Objective: To assess the risk of incident malignant neoplasms in patients with rheumatoid arthritis (RA) treated with bDMARDs...
November 1, 2017: JAMA Internal Medicine
https://www.readbyqxmd.com/read/28974987/sustained-remission-in-rheumatoid-arthritis-latest-evidence-and-clinical-considerations
#19
REVIEW
Sofia Ajeganova, Tom Huizinga
Sustained remission is an ultimate treatment goal in the management of patients with rheumatoid arthritis (RA). Historically the frequency of sustained remission was low but the frequency of achieved sustained remission is increasing over time. The last years' clinical studies of tight control targeted treatment and intervention trials of early use of intensive strategy suggest that these treatment strategies are associated with higher rates of sustained remission. Achievement of sustained remission, in particular but not limited to early sustained remission, can provide tapering and stopping disease-modifying antirheumatic drugs (DMARDs)...
October 2017: Therapeutic Advances in Musculoskeletal Disease
https://www.readbyqxmd.com/read/28970215/metabolic-and-cardiovascular-benefits-of-hydroxychloroquine-in-patients-with-rheumatoid-arthritis-a-systematic-review-and-meta-analysis
#20
Claire Rempenault, Bernard Combe, Thomas Barnetche, Cécile Gaujoux-Viala, Cédric Lukas, Jacques Morel, Charlotte Hua
OBJECTIVE: Cardiovascular disease (CVD) is the leading cause of mortality in patients with rheumatoid arthritis (RA). Hydroxychloroquine (HCQ) has been shown to improve survival rates in other inflammatory diseases. We aimed to assess the available literature on the cardiovascular impact of HCQ in patients with RA. METHODS: We systematically searched for studies evaluating the effects of HCQ on cardiovascular outcomes of known risk factors for CVD in patients with RA...
September 25, 2017: Annals of the Rheumatic Diseases
keyword
keyword
116670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"